Correcting Overall Survival for the Impact of Crossover Via a Rank-Preserving Structural Failure Time (RPSFT) Model in the RECORD-1 Trial of Everolimus in Metastatic Renal-Cell Carcinoma-Reference-Cited by-同舟云学术

Correcting Overall Survival for the Impact of Crossover Via a Rank-Preserving Structural Failure Time (RPSFT) Model in the RECORD-1 Trial of Everolimus in Metastatic Renal-Cell Carcinoma

Published:2012-10-17 Issue:6 Volume:22 Page:1258-1271
ISSN:1054-3406
Container-title:Journal of Biopharmaceutical Statistics
language:en
Short-container-title:Journal of Biopharmaceutical Statistics

Author:

Korhonen P.¹,Zuber E.²,Branson M.²,Hollaender N.²,Yateman N.³,Katiskalahti T.¹,Lebwohl D.⁴,Haas T.²

Affiliation:

1. a StatFinn Oy , Espoo , Finland

2. b Novartis Pharma AG , Basel , Switzerland

3. c SDE Services AG , Pratteln , Switzerland

4. d Novartis Pharmaceuticals , East Hanover , New Jersey , USA

Publisher

Informa UK Limited

Subject

Pharmacology (medical),Pharmacology,Statistics and Probability

Link

https://www.tandfonline.com/doi/pdf/10.1080/10543406.2011.592233

Reference21 articles.

1. Randomized Phase II Study of Multiple Dose Levels of CCI-779, a Novel Mammalian Target of Rapamycin Kinase Inhibitor, in Patients With Advanced Refractory Renal Cell Carcinoma

2. Inverse probability-of-censoring weights for the correction of time-varying noncompliance in the effect of randomized highly active antiretroviral therapy on incident AIDS or death

3. Effect of acyclovir on herpetic ocular recurrence using a structural nested model

4. Novel statistical analysis of long-term survival to account for crossover in a phase III trial of sunitinib (SU) vs. placebo (PL) in advanced GIST after imatinib (IM) failure

Cited by 28 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Survival analysis from the INCREASE study in PH-ILD: evaluating the impact of treatment crossover on overall mortality;Thorax;2023-11-18

2. Clinical trial considerations for pediatric cancer drug development;Journal of Biopharmaceutical Statistics;2023-02-07

3. Key considerations for choosing a statistical method to deal with incomplete treatment adherence in pragmatic trials;Pharmaceutical Statistics;2022-08-03

4. Adjusting Overall Survival Estimates of Macitentan in Pulmonary Arterial Hypertension After Treatment Switching: Results from the SERAPHIN Study;Advances in Therapy;2022-08-01

5. A modified weighted log-rank test for confirmatory trials with a high proportion of treatment switching;PLOS ONE;2021-11-15